Voyager Therapeutics Inc (NASDAQ:VYGR)‘s stock had its “outperform” rating reaffirmed by equities research analysts at Wedbush in a research report issued to clients and investors on Wednesday, May 10th. They currently have a $36.00 price objective on the stock. Wedbush’s target price would indicate a potential upside of 282.98% from the company’s current price.
A number of other analysts have also commented on VYGR. Zacks Investment Research lowered Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, January 18th. Cowen and Company restated a “buy” rating on shares of Voyager Therapeutics in a report on Friday, January 20th. Nomura began coverage on Voyager Therapeutics in a report on Wednesday, March 1st. They set a “buy” rating on the stock. Instinet began coverage on Voyager Therapeutics in a report on Wednesday, March 1st. They set a “buy” rating and a $31.00 target price on the stock. Finally, Chardan Capital reiterated a “neutral” rating and set a $13.00 target price on shares of Voyager Therapeutics in a report on Thursday, March 16th. Two investment analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Voyager Therapeutics has an average rating of “Buy” and a consensus price target of $27.50.
Voyager Therapeutics (NASDAQ:VYGR) opened at 9.40 on Wednesday. The firm’s market cap is $252.41 million. Voyager Therapeutics has a 52 week low of $8.48 and a 52 week high of $18.25. The company has a 50-day moving average of $9.81 and a 200 day moving average of $11.93.
Voyager Therapeutics (NASDAQ:VYGR) last issued its quarterly earnings results on Tuesday, May 9th. The company reported ($0.65) EPS for the quarter, missing analysts’ consensus estimates of ($0.54) by $0.11. The firm had revenue of $1.46 million during the quarter, compared to the consensus estimate of $3.70 million. Voyager Therapeutics had a negative net margin of 195.31% and a negative return on equity of 20.58%. On average, equities analysts predict that Voyager Therapeutics will post ($2.58) earnings per share for the current year.
TRADEMARK VIOLATION WARNING: “Voyager Therapeutics Inc (VYGR) Given “Outperform” Rating at Wedbush” was first published by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of U.S. & international copyright law. The original version of this piece of content can be accessed at https://www.com-unik.info/2017/06/05/wedbush-reiterates-outperform-rating-for-voyager-therapeutics-inc-vygr-updated-updated.html.
Several institutional investors have recently bought and sold shares of VYGR. Vanguard Group Inc. increased its position in Voyager Therapeutics by 9.3% in the first quarter. Vanguard Group Inc. now owns 417,571 shares of the company’s stock valued at $5,529,000 after buying an additional 35,447 shares during the last quarter. Adage Capital Partners GP L.L.C. increased its position in Voyager Therapeutics by 100.0% in the third quarter. Adage Capital Partners GP L.L.C. now owns 200,000 shares of the company’s stock valued at $2,402,000 after buying an additional 100,000 shares during the last quarter. State Street Corp increased its position in Voyager Therapeutics by 5.3% in the fourth quarter. State Street Corp now owns 165,503 shares of the company’s stock valued at $2,108,000 after buying an additional 8,257 shares during the last quarter. Partner Investment Management L.P. increased its position in Voyager Therapeutics by 519.7% in the third quarter. Partner Investment Management L.P. now owns 162,278 shares of the company’s stock valued at $1,948,000 after buying an additional 136,091 shares during the last quarter. Finally, Wellington Management Group LLP increased its position in Voyager Therapeutics by 17.4% in the first quarter. Wellington Management Group LLP now owns 131,312 shares of the company’s stock valued at $1,739,000 after buying an additional 19,450 shares during the last quarter. 39.95% of the stock is currently owned by institutional investors.
Voyager Therapeutics Company Profile
Voyager Therapeutics, Inc is a clinical-stage gene therapy company. The Company focuses on developing treatments for patients suffering from severe diseases of the central nervous system (CNS). The Company’s pipeline consists of programs for CNS indications, including advanced Parkinson’s disease; a monogenic form of amyotrophic lateral sclerosis (ALS); Huntington’s disease; Friedreich’s ataxia; frontotemporal dementia/Alzheimer’s disease, and severe chronic pain.
What are top analysts saying about Voyager Therapeutics Inc? – Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts’ recommendations for for Voyager Therapeutics Inc and related companies.